GSK Sees Excedrin Sales Growth As Consumers Visualize Headache Pain
Executive Summary
Excedrin Extra Strength US sales for the 12 months ending Aug. 12 were up 4.07% to $77.2m, but those figures don't include the 12,000 free packages of Excedrin gel tablets consumers ordered during GSK's the Limited Edition promotion. The firm offered Excedrin in packages marked with causes consumers commonly link with headaches: commuting, bad dating and "adulting."
You may also be interested in...
Glaxo Opts For Solo Navigation To Boost Control In Consumer Health Market
After announcing the $13bn acquisition of Novartis' 36.5% share of their JV, GSK said its Horlicks nutritional beverage line and its consumer health subsidiary in India, the source of most Horlicks sales, are potential divestments. The firm also will consider selling other consumer health nutrition products.
Consumer Business Reliable And Right At Home At GlaxoSmithKline
CEO Walmsley's familiarity with Glaxo's consumer health business was clear in her response to analysts' questions about the firm's future as a three-unit operation. The business marketing brands including Flonase and Excedrin is a more reliable revenue driver than the pharma business, she said.
'Migraine Experience' Debuts Excedrin Advertising By Glaxo/Novartis JV
Excedrin Migraine’s multi-channel campaign, the first major promotion for the brand since moving into the Glaxo/Novartis JV, incorporates "augmented reality" technology for a window into the struggles of migraine sufferers.